Alex Knapp is a senior editor covering healthcare, science, and cutting edge technology who joined Forbes in 2011. He's written dozens of profiles of entrepreneurs across a variety of fields and done deep dives into technological trends from superconductors to space travel to pharmaceuticals.
from a clinical trial of ISM001-055, which the company designed using generative AI in order to treat idiopathic pulmonary fibrosis, a chronic lung disease affecting around 100,000 Americans that makes breathing increasingly difficult as it progresses.
The phase IIa study, conducted in China, involved 71 patients who were randomized to either receive a placebo, a daily 30mg pill, a twice-daily dose of a 30mg pill, or a daily 60 mg pill. Across all patients, the majority of side effects were mild or moderate, the company said. Those who received the highest dose law improvement in lung function compared to the placebo group. The 60mg group also saw improvements in their quality of life.
Enveda takes advantage of modern computational biology to supercharge this effort, he explained. The company uses mass spectrometry to identify the chemical fingerprints of substances in biological samples, which enables them to process samples quickly without having to purify them. Then it trained transformer models to interpret those spectra and predict molecular structures.
ENV-294 was derived from a molecule that plants use to handle inflammation, Colluru said, but with a very different molecular pathway than that employed by existing anti-inflammatories used for dermatitis or other inflammatory conditions, which can have rough side effects. The next step for the company is to complete its first clinical trial, which he said should happen by the beginning of the second quarter next year.
The study found those taking semaglutide, the active ingredient in Ozempic and Wegovy, and liraglutide, the ingredient in Victoza, experienced reduced alcohol consumption and were less likely to be hospitalized for alcohol-related issues than their peers. Researchers warned the results of the study should be interpreted"cautiously" and that clinical trials will be needed to find if the improved outcomes were actually caused by the use of GLP-1 medications.
Artificial Intelligence Health Insurance Billionaires Trump Elon Musk Vaccines Rfk
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
EARLY TAVR: A Positive Trial That Fails to Inform Clinical DecisionsA trial suggests that patients with asymptomatic severe aortic stenosis should undergo early transcatheter aortic valve implantation, but John Mandrola, MD, sees flaws in the study design.
Read more »
From Clinical Trials to Clinical Practice: COX-2 InhibitionDr Maurie Markman discusses the implications of COX-2 therapy for patients with PIK3CA-activated colon cancer.
Read more »
Gotistobart Trial for NSCLC on Partial Clinical HoldThe FDA placed the hold on the phase 3 PRESERVE-003 trial of the antibody candidate due to varying results between patient populations, according to an SEC notice.
Read more »
Clinical trial for treating spinal cord injury using olfactory cell nerve bridgesRealizing a Phase I human clinical trial commencing to test the efficacy and safety of the transplantation of olfactory cell nerve bridges to treat chronic spinal cord injury.
Read more »
Intermountain team first to implement new aortic aneurysm treatment outside clinical trialIntermountain Medical Center in Murray has become the first U.S. hospital to perform a minimally invasive surgery outside of clinical trials to treat aortic aneurysm using a new FDA-approved device.
Read more »
Gene editing approach paves the way to first-in-human clinical trial for rare genetic diseaseNew research demonstrates the potential of precise genome editing technologies, called adenine base editors, to correct disease-causing mutations in stem cells from patients with X-linked chronic granulomatous disease (X-CGD), a rare genetic disorder characterized by high susceptibility to infections.
Read more »